Aayush Wellness Ltd

Dematerialisation status

• RTA processed dematerialisation requests and reported acceptance/rejection to depositories.
• Dematerialised securities were listed on the stock exchanges where the existing securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled after verification; depository registered owner updated within 15 days.

AGM details

• Held September 29, 2026 at 2:00 PM IST via VC/OAVM.
• Remote e-voting: Sept 26, 2026 9:00 AM to Sept 28, 2026 5:00 PM.
• Attendance: 37 members present; 41,524 on cut-off date.

Key resolutions

• Approve standalone financial statements, Board report, and Auditor’s report.
• Approve consolidated financial statements and Auditor’s report.
• Re-appoint director retiring by rotation.
• Appoint statutory auditors.

Voting status

• Combined remote and AGM voting results to be submitted to exchanges.
• Scrutinizer’s report to be placed on company website.

Director changes

• Directors to consider re-appointment of director retiring by rotation.

Auditor appointments

• Statutory auditors appointed for the company.

Aayush Wellness Ltd – Closure of Trading Window from Oct 01, 2026; will reopen 48 hours after the declaration of Unaudited Financial Results for the quarter and half year ending on September 30, 2026.

Record Date for AGM Voting

• Cut-off date for e-voting: September 22, 2026.
• Remote e-voting period: Sep 26, 2026 9:00 AM to Sep 28, 2026 5:00 PM.
• AGM date and time: Sep 29, 2026, 2:00 PM IST via VC/OAVM.
• Purpose: determine voting eligibility for AGM resolutions.

MD resignation details

• Naveenakumar Kunjaru, Managing Director, resigns from Aayush Wellness Limited.
• Resignation effective from September 9, 2026.
• Reason: personal and family commitments.
• No immediate replacement or appointment disclosed.
• Annexure confirms no further material reasons beyond those stated.
• External directorships disclosed: Empower India Limited—Non-Executive Independent Director; multiple chair roles.
• Filed with stock exchanges under SEBI LODR Regulation 30.

Financial performance

• Standalone revenue from operations: ₹15,545.08 Lakhs; total income: ₹15,806.10 Lakhs; PAT: ₹401.88 Lakhs.
• Consolidated revenue from operations: ₹15,548.15 Lakhs; total income: ₹15,809.17 Lakhs; PAT: ₹398.04 Lakhs.
• Revenue growth: FY26 revenue up 112% YoY; total income up 115% YoY.
• Interim dividend paid: ₹0.025 per equity share.
• Tax: current tax ₹41.50 Lakhs; deferred tax credit ₹0.81 L; net tax ₹40.70 Lakhs.
• Cash & cash equivalents: standalone ₹58.70 Lakhs; consolidated ₹226.62 Lakhs.
• Borrowings: standalone ₹404.53 Lakhs; consolidated ₹473.53 Lakhs.
• EPS: standalone ₹0.83; consolidated ₹0.82.
• Authorized capital ₹9 Crores; issued paid-up capital ₹486.72 Lakhs.

Strategic growth & business model

• Three verticals: Herbal Alternatives, Nutraceuticals, Aayush Labs diagnostics platform.
• FY26 revenue grew 112% with launches and expanded distribution driving demand.
• Q4 FY26 revenue grew 117% YoY; sequential QoQ growth ~9%.
• Product launches: Liver Detox, Brain Fuel, Sleep Gummies, Immunity Booster, Dia Shield.
• Integrated ecosystem aims to link diagnostics data to nutraceutical recommendations.
• Distribution expansion targets Tier 2/3 towns and e-commerce channels.

Subsidiaries & corporate structure

• Five wholly-owned subsidiaries as of 31 Mar 2026: Aayush HealthSciences, Aayush Worldwide, Aayush Labs, Aayush Ventures, Aayush International Pte. Ltd.
• All subsidiaries 100% owned; international subsidiary in Singapore (Aayush International Pte. Ltd.).
• Effective dates: HealthSciences (Nov 7, 2024); Worldwide (Jan 4, 2025); Labs (Aug 26, 2025); Ventures (Aug 27, 2025); International (Sept 26, 2025).
• Registered office shifted from Delhi to Maharashtra; compliance with MCA/SEBI disclosures.

Governance & controls

• Board meetings totaled 14 in FY2025-26; governance frameworks in place.
• Auditors: JMS & Co. LLP resigned Feb 14, 2026; M/s A. Raghavendra Rao & Associates appointed May 21, 2026.
• Secretarial Auditor: M/s NKM & Associates; casual vacancy due to auditor resignation noted.
• Internal controls endorsed; ISO 9001 and ISO 22000 certifications maintained.

Dividends, AGM & corporate actions

• FY2025-26 interim dividend paid; no final dividend declared.
• 42nd AGM scheduled for Sep 29, 2026 via VC/OAVM.
• Remote e-voting from Sep 26 to Sep 28, 2026; shareholding as on Sep 22, 2026 cut-off date.

Capital structure & liquidity

• Authorised capital ₹9.00 Crores; issued & paid-up ₹486.72 Lakhs.
• Borrowings at 31 Mar 2026: standalone ₹404.53 Lakhs; consolidated ₹473.53 Lakhs.
• Cash & equivalents: standalone ₹58.70 Lakhs; consolidated ₹226.62 Lakhs.
• Inventories: ₹66.65 Lakhs; Trade receivables: ₹14.82 Lakhs (standalone); ₹15.00 Lakhs (consolidated).

Outlook & risks

• Management expects continued growth supported by nutraceutical and diagnostics markets.
• Strategic priorities include deeper Aayush Labs integration with nutraceuticals and expanded Tier 2/3 reach.
• Risks include regulatory classification of nutraceuticals, competition, supply-chain volatility, and execution scale.

Product portfolio & innovation

• Nutraceuticals span Calcium + Vitamins, Sleep Gummies, Beauty Gummies, Brain Fuel, Gut Fuel, Immunity, Liver Detox, Dia Shield.
• Herbal Masala anchors Herbal Alternatives; Aayush Labs offers diagnostics and testing services.
• Innovation blends Ayurveda with modern science; focus on condition-specific, high-margin formats.

Customer reach & distribution

• Dual-channel approach: offline retail/pharmacy plus digital/e-commerce.
• Aayush Labs aims to build a services model with home testing and telemedicine touchpoints.

AGM Details

• AGM date/time: 29 September 2026 at 02:00 PM via VC/OAVM.
• Record date for voting: 22 September 2026.
• Remote e-voting window: 26–28 September 2026.
• Attendance through VC/OAVM counts toward quorum.

Key Resolutions (Ordinary)

• Resolution 1: Adopt Standalone Financial Statements for year ended 31 March 2026.
• Resolution 2: Adopt Consolidated Financial Statements for year ended 31 March 2026.
• Resolution 3: Re-appoint Gavadu Patil as Director, retire by rotation.
• Resolution 4: Appoint M/s. A. Raghavendra Rao & Associates as Statutory Auditors for 5 years.

Dividend

• Interim dividend of Rs 0.025 per share already paid.

Directors & Auditors

• Director Gavadu Patil to be re-appointed; attendance 14 meetings in 2025-26.
• Statutory auditor tenure: five years; remuneration to be decided by Board.

General Notes

• Proxy facility not available due to VC/OAVM format.
• Scrutinizer appointed: Aarju Agrawal & Associates.

Key Decisions

• Re-appointment of Gavadu Patil as Director liable to retirement by rotation; effective Sept 29, 2026, subject to approval.
• Appointment of Statutory Auditor M/s A. Raghavendra Rao & Associates for five years, subject to member approval.
• Notice of 42nd AGM and Board's Report for year ended March 31, 2026.
• Convene 42nd AGM on Sept 29, 2026 at 2:00 PM via VC/OAVM.
• Cut-off date for voting eligibility fixed at Sept 22, 2026.
• Remote e-voting from Sept 26, 2026 09:00 AM IST to Sept 28, 2026 05:00 PM IST.
• Appointment of Scrutinizer Aarju Agrawal & Associates for the 42nd AGM.